(RPRX) Royalty Pharma plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(RPRX) Royalty Pharma plc Complete Analysis Pack
Unlock Strategic Clarity
This Royalty Pharma plc BCG Matrix helps you see how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The page already shows a real preview of the actual report content, so you can check the format and depth before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
Vertex CF franchise, multi-billion-dollar sales
Royalty Pharma’s core "Star" exposure is the Vertex cystic fibrosis franchise, led by Trikafta/Kaftrio, which helped Vertex generate about $11.0 billion in 2024 revenue. The franchise still posts strong cash flow, with growth from wider labels and more geographies. That scale and durability keep Royalty Pharma’s royalty stream tied to one of rare disease’s best cash machines.
Nurtec ODT/Vydura, strong migraine growth
Nurtec ODT/Vydura stays a Star for Royalty Pharma plc because it is still winning new migraine users in both acute and preventive care. In 2025, prescription growth kept royalty receipts moving up as broad adoption outpaced franchise maturity. The asset’s dual-label profile and expanding neurology use make it a fast-growing royalty with room left to run.
Evrysdi, expanding SMA adoption
Evrysdi sits in a growing SMA market; spinal muscular atrophy affects about 1 in 10,000 births, and treatment uptake keeps rising as diagnosis gets earlier. The drug is approved in more than 100 countries, so Royalty Pharma plc still has room for royalty growth as penetration improves. In a high-value rare-disease niche, every added patient can lift recurring income.
Alyftrek, 2024 CF launch
Alyftrek, Vertex Pharmaceuticals Incorporated’s 2024 CF launch, is a Star-type asset if uptake stays strong because it adds a new option in a market that already generated about $10.8 billion in Vertex revenue in 2024. It was FDA-approved in December 2024 for cystic fibrosis patients age 6+ with at least one F508del or another responsive mutation, and broader use can lift the whole CF franchise, not just steal share.
- 2024 launch supports franchise growth.
- CF market is still expanding.
- Strong uptake can protect Star status.
Voranigo, launch-stage oncology royalty
Voranigo, Royalty Pharma plc’s royalty on Servier’s vorasidenib, is a launch-stage oncology asset with a long runway after U.S. FDA approval in August 2024 for IDH-mutant grade 2 glioma. In INDIGO, it cut the risk of progression or death by 61% and lifted median progression-free survival to 27.7 months vs 11.1 months. Early use in this defined molecular niche can drive fast royalty growth, so it fits a Star profile while uptake builds.
- FDA approval: August 2024
- INDIGO PFS: 27.7 vs 11.1 months
- 61% lower progression risk
Royalty Pharma’s Star Assets Keep Driving Growth
Royalty Pharma plc’s Stars are led by Vertex’s CF franchise, where 2024 revenue was about $11.0 billion and new launch Alyftrek can extend growth. Nurtec ODT/Vydura also stays a Star as 2025 prescriptions rose in both acute and preventive migraine use. Evrysdi keeps scaling in SMA, while Voranigo adds a fresh oncology growth leg after its August 2024 FDA approval.
| Asset | Star signal |
|---|---|
| Trikafta/Kaftrio | ~$11.0B 2024 revenue |
| Nurtec ODT/Vydura | 2025 prescription growth |
| Evrysdi | More than 100 countries |
| Voranigo | FDA approved Aug 2024 |
What is included in the product
Detailed Word Document
Royalty Pharma plc BCG Matrix: a concise view of its drugs and royalties across Stars, Cash Cows, Question Marks, and Dogs.
Editable Excel File
One-page BCG Matrix for Royalty Pharma plc that clarifies portfolio positioning at a glance
Reference Sources
Provides a credible source trail for Royalty Pharma plc, helping investors verify assumptions fast and make better decisions with confidence.
Cash Cows
Xtandi, established prostate-cancer royalty
Xtandi stayed a mature blockbuster for Royalty Pharma plc, with global sales above $5 billion in 2025 and recurring royalty cash tied to an established prostate-cancer market. That kind of scale and repeat demand fits a Cash Cow: high share, low new-user growth, steady cash flow.
Royalty income from Xtandi is less about fast expansion and more about durable harvest, which is why it ranks as a classic BCG Cash Cow.
Imbruvica, mature hematology royalty
Imbruvica remains a mature cash cow for Royalty Pharma plc, with long-running royalty inflows and limited added selling spend. Even with tighter competition, it still supports cash generation because the royalty stream keeps coming without heavy promotion. In BCG terms, this is a classic low-investment, high-cash asset.
Tysabri, long-running MS royalty
Tysabri has been on the market since 2004, so it is a mature 20+ year MS franchise with limited growth left. Still, it keeps generating royalty cash for Royalty Pharma plc because demand for the therapy remains durable. That steady, low-growth, high-cash profile fits a Cash Cow in the BCG Matrix.
Promacta/Revolade, large hematology franchise
Promacta/Revolade is a mature hematology asset and a classic Cash Cow for Royalty Pharma plc: demand is steady, not fast-growing, so it fits a low-growth, high-cash profile. Its large global franchise and broad use in ITP, aplastic anemia, and other blood disorders support predictable royalty inflows that still matter for 2025 cash generation.
- Stable demand, low growth
- Broad hematology franchise
- Predictable royalty cash flow
- Useful cash generator
Spinraza, mature SMA royalty tail
Spinraza is a mature SMA asset: Biogen reported 2024 Spinraza revenue of about $1.8 billion, but growth is slower as newer SMA therapies take share. For Royalty Pharma plc, that still means recurring royalty cash from a rare-disease market with sticky use and long-tail demand, so it fits Cash Cow better than Star.
- Mature product, slower growth
- Still earns recurring royalties
- Rare-disease demand stays durable
- Cash Cow, not high-growth Star
Royalty Pharma’s Cash Cows Keep Printing Steady Cash in 2025
Royalty Pharma plc’s Cash Cows are mature royalty assets that still throw off steady cash in 2025. Xtandi topped $5 billion in global sales, Spinraza was about $1.8 billion in 2024 revenue, and Imbruvica, Tysabri, and Promacta/Revolade remain low-growth, high-cash franchises that need little extra spend.
| Asset | 2025/2024 signal | BCG role |
|---|---|---|
| Xtandi | Above $5B sales | Cash Cow |
| Spinraza | About $1.8B revenue | Cash Cow |
Get Your Copy
Royalty Pharma plc Reference Sources
The Royalty Pharma plc BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the complete, professionally formatted report ready for use. Once purchased, the full file is delivered instantly for download, editing, or presentation. What you see here is what you get.
Dogs
Oxbryta, withdrawn in 2024
Oxbryta was withdrawn in 2024, so its growth path and forward royalties are effectively gone. Pfizer pulled the drug after post-marketing safety data showed 15 deaths and 5 vaso-occlusive crises in the approval-trial group, with no clear net benefit. That fits the Dog profile: discontinued commercial use and weak future cash flow. Capital tied to it is unlikely to earn strong returns.
Legacy hepatitis C royalty tail
Royalty Pharma plc’s legacy hepatitis C royalty tail fits Dogs: the cure wave has already peaked, and direct-acting antivirals now cure more than 95% of patients, so new demand is thin.
As generic entry and lifecycle erosion spread, royalty cash flows shrink fast; many older HCV franchises have already seen revenue fall by more than 90% from peak levels.
That leaves limited inflow and little growth, so the tail usually behaves like a low-return Dog in the BCG matrix.
Legacy HIV royalty tail
Legacy HIV royalty tail assets in Royalty Pharma plc are usually mature, low-growth names. With many HIV drugs now in long-cycle saturation, upside is thin unless a product keeps unusual share or has strong patent life. That makes this a weak BCG fit, since a tail asset needs fast cash flow growth, not just steady royalty cash.
Post-LOE MS royalty tail
Post-LOE MS royalties fit a Dog profile: the market can stay large, but once exclusivity ends and generics or biosimilars hit, royalty rates and share usually slide fast. For Royalty Pharma plc, these tails tend to be low-growth cash flows, with no clear path back to durable expansion.
- LOE cuts pricing power.
- Competition erodes share.
- Cash still comes in, but fades.
- Dogs rarely re-rate.
Small-molecule expiry tail
Royalty Pharma plc’s small-molecule expiry tail fits the Dogs bucket: once patents roll off, royalties usually fade into low-return cash flows, with little growth left. In 2025, Royalty Pharma reported $2.5 billion in adjusted cash receipts and $2.0 billion in adjusted EBITDA, but the expiring tail still deserves only light capital. The BCG call is simple: harvest it, watch it, and don’t fund it like a growth engine.
- Low-growth, post-expiry cash flow
- Keep capital spend near zero
- Monitor for faster royalty erosion
Royalty Pharma’s fading royalty dogs still throw off cash
Royalty Pharma plc’s Dogs are old, post-peak royalty tails with little growth left. In 2025, it still produced $2.5 billion of adjusted cash receipts and $2.0 billion of adjusted EBITDA, but these assets no longer need heavy capital. Oxbryta was withdrawn in 2024, and legacy HCV and post-LOE MS royalties keep fading.
| Dog asset | 2025 signal | BCG view |
|---|---|---|
| Oxbryta | Withdrawn in 2024 | Dog |
| HCV tail | Declining demand | Dog |
| Post-LOE MS | Generic erosion | Dog |
Question Marks
Aficamten, late-stage cardiology royalty
Aficamten sits in hypertrophic cardiomyopathy, a market that affects about 1 in 500 adults, or roughly 660,000 people in the U.S. alone. That gives Royalty Pharma plc real upside if uptake scales.
But commercial share is still early and returns are not yet visible, so the royalty stream is not proven. Late-stage clinical data are promising, but the asset still fits the Question Mark box: high growth, uncertain cash yield.
If adoption accelerates after launch, Aficamten could become a meaningful royalty driver; if it stalls, the payoff stays limited.
Apitegromab, neuromuscular development asset
Apitegromab targets spinal muscular atrophy, a rare disease affecting about 1 in 10,000 live births, so the addressable pool is small but high value. Royalty Pharma plc has exposure to an asset that is still pre-commercial, so market share and cash flow are not yet proven. If Phase 3 adoption scales, it could move from Question Mark to Star, but that needs heavy launch investment first.
Roctavian, gene-therapy launch asset
Roctavian is a one-time gene therapy in a market still in early adoption, with uptake hinging on payer coverage and specialist center access. BioMarin said 2024 Roctavian revenue was still only in the tens of millions of dollars, far below blockbuster scale, so Royalty Pharma’s exposure remains a Question Mark. Fast growth is possible, but low current share and reimbursement risk keep it uncertain.
Rare-disease pipeline, 10 development assets
Royalty Pharma plc’s rare-disease question marks include about 10 development assets, with upside tied to trial wins, approvals, and fast uptake. These programs can shift into cash generators quickly, but until then they need funding and carry binary risk. For Royalty Pharma plc, the value gap is wide: one approval can re-rate a royalty stream, while delays can keep returns muted.
- About 10 assets are still in development
- Approval can drive rapid value creation
- Until then, capital use stays high
- Outcomes remain uncertain and binary
Oncology and immunology pipeline, early commercial risk
Royalty Pharma plc’s oncology and immunology pipeline fits Question Marks: the market is huge, but cash flows are still unproven. GLOBOCAN 2022 counted 20.0 million new cancer cases and 9.7 million deaths, so the upside is real, yet clinical, FDA, and payer risk stays high until approval and reimbursement land.
- Large market, low current share
- High approval and launch risk
- Upside depends on proof
That makes these royalty interests classic Question Marks for Royalty Pharma plc.
Royalty Pharma’s Big Bets Still Need Proof of Cash Flow
Aficamten, apitegromab, and Roctavian are still Question Marks for Royalty Pharma plc: each targets a large or valuable niche, but cash flow is not yet proven. Aficamten’s HCM market is about 1 in 500 adults; apitegromab serves SMA, about 1 in 10,000 live births; Roctavian revenue was still only in the tens of millions in 2024. Upside is real, but launch, payer, and trial risk stay high.
| Asset | Signal |
|---|---|
| Aficamten | Large market, early share |
| Apitegromab | Pre-commercial, binary |
| Roctavian | Low revenue, adoption risk |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.